المستودع الأكاديمي جامعة المدينة

Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study.

أعرض تسجيلة المادة بشكل مبسط

dc.contributor Epicentre, Paris, France.
dc.creator Nathan, N
dc.creator Borel, T
dc.creator Djibo, A
dc.creator Evans, D
dc.creator Djibo, S
dc.creator Corty, J F
dc.creator Guillerm, M
dc.creator Alberti, K P
dc.creator Pinoges, L
dc.creator Guerin, P J
dc.creator Legros, D
dc.date 2008-04-14T12:02:10Z
dc.date.accessioned 2017-01-31T07:10:42Z
dc.date.available 2017-01-31T07:10:42Z
dc.identifier Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study., 366 (9482):308-13 Lancet
dc.identifier 1474-547X
dc.identifier 16039333
dc.identifier 10.1016/S0140-6736(05)66792-X
dc.identifier http://hdl.handle.net/10144/23232
dc.identifier http://fieldresearch.msf.org/msf/handle/10144/23232
dc.identifier Lancet
dc.identifier.uri http://dspace.mediu.edu.my:8181/xmlui/handle/10144/23232
dc.description BACKGROUND: In sub-Saharan Africa in the 1990s, more than 600,000 people had epidemic meningococcal meningitis, of whom 10% died. The current recommended treatment by WHO is short-course long-acting oily chloramphenicol. Continuation of the production of this drug is uncertain, so simple alternatives need to be found. We assessed whether the efficacy of single-dose treatment of ceftriaxone was non-inferior to that of oily chloramphenicol for epidemic meningococcal meningitis. METHODS: In 2003, we undertook a randomised, open-label, non-inferiority trial in nine health-care facilities in Niger. Participants with suspected disease who were older than 2 months were randomly assigned to receive either chloramphenicol or ceftriaxone. Primary outcome was treatment failure (defined as death or clinical failure) at 72 h, measured with intention-to-treat and per-protocol analyses. FINDINGS: Of 510 individuals with suspected disease, 247 received ceftriaxone, 256 received chloramphenicol, and seven were lost to follow-up. The treatment failure rate at 72 h for the intention-to-treat analysis was 9% (22 patients) for both drug groups (risk difference 0.3%, 90% CI -3.8 to 4.5). Case fatality rates and clinical failure rates were equivalent in both treatment groups (14 [6%] ceftriaxone vs 12 [5%] chloramphenicol). Results were also similar for both treatment groups in individuals with confirmed meningitis caused by Neisseria meningitidis. No adverse side-effects were reported. INTERPRETATION: Single-dose ceftriaxone provides an alternative treatment for epidemic meningococcal meningitis--its efficacy, ease of use, and low cost favour its use. National and international health partners should consider ceftriaxone as an alternative first-line treatment to chloramphenicol for epidemic meningococcal meningitis.
dc.language en
dc.publisher Elsevier
dc.relation http://www.thelancet.com
dc.rights Reproduced on this site with permission of Elsevier Ltd. Please see www.thelancet.com for further relevant comment.
dc.title Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study.


الملفات في هذه المادة

الملفات الحجم الصيغة عرض

لا توجد أي ملفات مرتبطة بهذه المادة.

هذه المادة تبدو في المجموعات التالية:

أعرض تسجيلة المادة بشكل مبسط